As of mid-2025, the FDA reported approximately 270 active drug shortages in the United States. The products affected are not obscure or niche — they include sterile injectables, antibiotics, and chemotherapy agents that patients and clinicians depend on daily. This figure, close to record highs, reflects systemic vulnerabilities that years of geopolitical disruption, trade policy shifts, and post-pandemic inventory corrections have made impossible to ignore.
For pharmaceutical supply chain leaders and senior executives, 2026 is a year of reckoning — and of opportunity. The companies building truly resilient supply chains now are converting a cost centre into a strategic asset.
Understanding the Current Pressure Points
Tariff volatility and geopolitical realignment
The US pharmaceutical supply chain faces significant exposure to trade policy shifts. Proposed pharmaceutical import tariffs could increase annual US drug costs by nearly $51 billion and result in consumer price increases of up to 12.9% if passed through fully. Several firms have reported API cost increases of 12% to 20% on widely used molecules including amoxicillin, acetaminophen, and metformin.
The US currently sources approximately 80% of its API imports from China and India. This concentration has become a recognised strategic risk. The potential passage of the BIOSECURE Act — which passed both the House and Senate and awaited presidential approval as of late 2025 — is expected to accelerate the reshoring and nearshoring of production for companies dependent on specific Chinese contract manufacturers.
DSCSA compliance pressure
The US Drug Supply Chain Security Act (DSCSA) exemptions for manufacturers and repackagers expired in May 2025 and for wholesale distributors in August 2025. Non-serialised, non-auditable supply chain architectures now carry material compliance and operational risk. Organisations that have delayed full serialisation integration are operating in an increasingly exposed position.
The drug shortage structural problem
Drug shortages stem from multiple, interconnected causes: single-source API dependencies, low generic drug margins that disincentivise redundant production capacity, increased demand in oncology and anaesthetics, and logistics disruptions cascading from geopolitical events. Regulators view these disruptions not as logistical inconveniences but as quality system failures — reflecting inadequate supplier qualification, insufficient inventory buffers, and weak risk management frameworks.
The Three Pillars of Supply Chain Resilience in 2026
1. Supplier diversification and geographic rebalancing
The post-pandemic era has definitively shifted strategic thinking from just-in-time to what supply chain professionals describe as just-in-case manufacturing. Safety stock coverage among pharmaceutical companies increased to 75 days in 2025, locking an estimated $8 billion in additional working capital industry-wide. Beyond inventory, companies are qualifying secondary and tertiary suppliers for critical raw materials and, in some cases, actively relocating portions of API production.
Johnson & Johnson announced a $55 billion US manufacturing investment in part as a hedge against tariff and geopolitical risk. Eli Lilly has targeted supplying all US needs from American-made facilities, accelerating a $27 billion domestic expansion. These decisions reflect a calculation that supply chain security now justifies higher operating costs.
2. Digital visibility and AI-powered control towers
End-to-end supply chain visibility has become a non-negotiable element of resilience planning. Pfizer's digital supply chain control tower provides real-time inventory visibility across its global network, using predictive analytics to dynamically adjust stock and distribution to reduce disruption risk.
Digital twin of the supply network maintains a continuously refreshed view of inventory, in-transit shipments, and partner capacity — ingesting IoT, ERP, transportation, and warehouse data in real time and projecting inbound supply against production commitments. More than 60% of major pharmaceutical companies are already using AI to support manufacturing processes, including supply chain optimisation.
3. Regulatory alignment of supply chain governance
Regulators increasingly treat supply chain resilience as a direct GMP compliance matter, not a separate operational topic. FDA inspections are evaluating supplier qualification protocols, risk assessments, and real-time performance monitoring as indicators of quality system maturity. Companies that invest in supply chain governance are better positioned in regulatory interactions.
The CDMO and CRO Dimension
Contract manufacturers and contract research organisations sit at a particularly sensitive point in the supply chain. CDMOs managing supply chain challenges in 2026 are navigating API shortages, cold chain complexity, and the shifting demands of sponsors reshoring production. The BIOSECURE Act, if enacted, will create additional pressure on CDMOs to demonstrate geographic independence from Chinese API suppliers. This is already reshaping how pharmaceutical companies evaluate outsourcing relationships: supply chain security and regulatory independence are now weighted alongside cost and capability in CDMO selection.